Coherus Oncology (CHRS) Share-based Compensation (2012 - 2026)

Coherus Oncology has disclosed Share-based Compensation across 15 years of filings, most recently posting $2.6 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 52.35% year-over-year to $2.6 million; the TTM figure through Jun 2026 stood at $11.1 million (down 53.67% YoY), while the FY2025 annual figure was $29.2 million, up 1.9% from the prior year.
• Share-based Compensation came in at $2.6 million for Q2 2026 at Coherus Oncology, up from $2.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.8 million in Q2 2022 to a low of $2.4 million in Q1 2026.
• Average Share-based Compensation over 5 years is $8.0 million, with a median of $7.3 million recorded in 2024.
• Year-over-year, Share-based Compensation grew 19.45% in 2022 and tumbled 56.39% in 2025.
• Over 5 years, Share-based Compensation stood at $11.7 million in 2022, then declined by 7.91% to $10.8 million in 2023, then sank by 40.88% to $6.4 million in 2024, then plunged by 56.39% to $2.8 million in 2025, then fell by 7.22% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.6 million in Q2 2026, $2.4 million in Q1 2026, and $2.8 million in Q4 2025.